Legacy Capital Wealth Partners LLC Has $201,000 Stock Position in Perrigo Company plc (NYSE:PRGO)

Legacy Capital Wealth Partners LLC cut its position in shares of Perrigo Company plc (NYSE:PRGO) by 44.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,251 shares of the company’s stock after selling 5,005 shares during the period. Legacy Capital Wealth Partners LLC’s holdings in Perrigo were worth $201,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of PRGO. Qube Research & Technologies Ltd bought a new position in Perrigo during the third quarter worth about $5,447,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Perrigo in the 3rd quarter valued at $2,006,000. Teachers Retirement System of The State of Kentucky grew its position in Perrigo by 94.1% in the third quarter. Teachers Retirement System of The State of Kentucky now owns 46,118 shares of the company’s stock valued at $1,473,000 after acquiring an additional 22,354 shares during the period. Patriot Financial Group Insurance Agency LLC raised its stake in Perrigo by 4.1% during the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 9,627 shares of the company’s stock worth $310,000 after acquiring an additional 380 shares in the last quarter. Finally, Blair William & Co. IL lifted its holdings in shares of Perrigo by 170.5% during the third quarter. Blair William & Co. IL now owns 25,023 shares of the company’s stock valued at $799,000 after acquiring an additional 15,774 shares during the period. 95.91% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Robert Willis purchased 6,000 shares of the business’s stock in a transaction dated Thursday, February 29th. The shares were bought at an average price of $25.87 per share, with a total value of $155,220.00. Following the purchase, the executive vice president now directly owns 25,105 shares in the company, valued at approximately $649,466.35. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, EVP Robert Willis bought 6,000 shares of the firm’s stock in a transaction dated Thursday, February 29th. The stock was bought at an average cost of $25.87 per share, for a total transaction of $155,220.00. Following the transaction, the executive vice president now owns 25,105 shares of the company’s stock, valued at $649,466.35. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Patrick Lockwood-Taylor bought 9,500 shares of the business’s stock in a transaction on Thursday, February 29th. The stock was purchased at an average price of $26.54 per share, for a total transaction of $252,130.00. Following the completion of the acquisition, the chief executive officer now owns 20,500 shares of the company’s stock, valued at approximately $544,070. The disclosure for this purchase can be found here. Insiders acquired a total of 17,990 shares of company stock valued at $475,227 over the last ninety days. Insiders own 0.40% of the company’s stock.

Analysts Set New Price Targets

PRGO has been the topic of several analyst reports. StockNews.com raised shares of Perrigo from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Piper Sandler lifted their target price on shares of Perrigo from $35.00 to $39.00 and gave the company an “overweight” rating in a research note on Monday, April 8th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $42.00 price target on shares of Perrigo in a report on Friday, April 12th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Perrigo from $48.00 to $41.00 and set an “overweight” rating on the stock in a report on Wednesday, February 28th.

Perrigo Trading Up 2.7 %

NYSE:PRGO opened at $32.80 on Tuesday. The stock’s fifty day moving average price is $30.54 and its two-hundred day moving average price is $30.82. Perrigo Company plc has a 52-week low of $25.77 and a 52-week high of $40.28. The company has a quick ratio of 1.07, a current ratio of 1.79 and a debt-to-equity ratio of 0.76.

Perrigo (NYSE:PRGO) last issued its quarterly earnings results on Tuesday, February 27th. The company reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.03. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.17 billion. Perrigo had a positive return on equity of 7.34% and a negative net margin of 0.27%. The firm’s revenue for the quarter was up .1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.75 earnings per share. On average, research analysts forecast that Perrigo Company plc will post 2.55 EPS for the current year.

Perrigo Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 26th. Stockholders of record on Friday, March 8th were given a dividend of $0.276 per share. This is a boost from Perrigo’s previous quarterly dividend of $0.27. The ex-dividend date was Thursday, March 7th. This represents a $1.10 annualized dividend and a dividend yield of 3.37%. Perrigo’s payout ratio is currently -1,100.00%.

About Perrigo

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.